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Abstract 
FUNCTIONAL CONSEQUENCES OF MATRIX METALLOPROTEINASE-1 OVER- 
EXPRESSION IN HUMAN GLIOMAS 
By Emily Mullet 
A thesis submitted in partial fulfillment of the requirements for .the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006 
Major Director: Helen L. Fillmore, PhD 
Assistant Professor, Departments of Neurosurgery, Anatomy and Neurobiology, 
Physiology, School of Medicine and the 
Department of Phannaceutics, School of Pharmacy 
Malignant brain tumors are among the deadliest of human cancers. Despite recent 
advancements in conventional therapies, glioblastomas remain incurable, largely due to 
their ability to invade surrounding tissue. Matrix metalloproteinases are thought to 
contribute to the invasive phenotype of human gliomas. Absent in normal brain, matrix 
metalloproteinase-1 (MMP-1) has been shown to be present in gliomas, and in particular in 
glioblastoma multiforme (GBM). To begin to examine the role of MMP-1 in these tumors, 
two human glioma cell lines were stably transfected with MMP-1 cDNA. Confirmation of 
MMP- 1 over-expression in these cells was achieved through real-time PCR and Western 
ix 
blot analysis. The functional consequences of MMP- 1 over-expression were analyzed 
using a collagen type-I invasion assay along with clonogenic and ATP viability assays. 
Data presented demonstrate that MMP-1 over-expressing cells were more invasive in both 
cell types and interestingly more clonogenic in one of the glioma cell lines, supporting a 
possible role for MMP-1 in glioma growth and invasion. 
CHAPTER 1 Introduction 
1.1 Overview of Brain Tumors 
Although the incidence of brain tumors is arguably on the rise, there rests little 
debate that the lethality of brain cancer requires immediate attention. Gliomas, the most 
prevalent type of primary brain tumor, occur in approximately five to ten people per 
100,000 individuals and remain incurable'. A defining feature of human gliomas is their 
ability to infiltrate healthy brain tissue, thereby escaping conventional therapies. For this 
reason, the prognosis for these malignant tumors is extremely poor. The World Health 
Organization (WHO) devised a system of glioma classification and acknowledges four 
grades of tumor (I-IV). Grade I tumors are benign whereas grades 11,111, and IV reflect the 
degree of tumor malignancy, grade IV being the most malignant. Glioblastoma 
multiforme (GBM), a grade IV tumor, is the deadliest of all gliomas with a median 
survival time of only 9-12 months2. These tumors are histologically characterized by 
dense cellularity, necrosis, and microvascular proliferation and are usually located in the 
fiontotemporal region or parietal lobes of the brain3. Less than three percent of people 
with GBMs survive five years after their diagnosis and seventy percent of all grade I1 
tumors progress to a higher malignancy tumor within five to ten years2. 
Surgical removal of the tumor is most often the primary form of treatment followed 
by radiation or chemotherapy. However, these treatments are not curative. Despite 
1 
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advances in surgical technique, chemotherapy and radiation treatments, as well as a better 
understanding of genetic components and how they relate to or determine the degree of 
tumor malignancy, there have been few advances in glioma treatment during the past 20 
years. In most cases the tumor recurs following surgical resection, thus treatment options 
can only extend survival time and attempt to temporarily relieve symptoms or restore 
functionality. A better understanding of brain tumor biology and the mechanisms behind 
malignant tumor invasion is essential to better treat, contain, and prevent infiltration of 
tumor cells into neighboring brain tissue. 
1.2 Tumor Cell Invasion 
Tumor invasion occurs when extracellular matrix (ECM) components are degraded, 
forging a path for tumor cells to infiltrate healthy tissue. Although some cancers, namely 
breast and lung cancers, will metastasize to the brain, primary brain tumors rarely spread to 
regions outside of the central nervous system3. However, primary brain cancer, 
specifically the gliomas, remains one of the most aggressively invasive and deadly of all 
cancers. 
Although the mechanisms behind tumor cell invasion are poorly understood, tumor 
cells have the ability to move through the extracellular matrix. Composed of various 
proteoglycans, myelin fibers, and glycoproteins such as fibronectin, tenascins, and 
laminins, the ECM is a dynamic matrix that houses many biologically active molecules 
and allows for little cell motility4. However, during tumor growth, the ECM may become 
more soluble as matrix components are degraded, allowing invading cells to infiltrate 
surrounding tissue. Tumor invasion is a biologically complex process involving proteases 
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which breakdown ECM, and molecules released from proteolytic activity that perpetuate 
various signaling pathways to induce proliferation, further matrix degradation, and 
facilitate penetration through the basement membrane. Three cell capabilities are required 
for tumor invasion through the ECM; cells must possess the ability to proteolyze ECM 
components, modify cell attachment and detachment processes, and migrate through 
matrix that has been previously altered by proteolytic degradation5. The activation of 
various cell signaling pathways facilitates matrix breakdown and the processes necessary 
to provide tumor cell movement into healthy tissue. 
Brain tumors and the surrounding healthy brain tissue secrete a host of growth 
factors, proteases, and proteins which participate in various cell signaling pathways to 
promote proliferation and invasion. As a result, matrix degradation occurs not only 
through a physical proteolytic shredding of matrix components, but through chemically 
derived cell-cell and cell-matrix communication. Members of the matrix metalloproteinase 
family, plasminogen activators, and molecules involved in integrin signaling play a role in 
matrix degradation and invasion facilitation3. Because invasion occurs via numerous 
mechanisms and through complex cell signaling cross-talk, therapeutic efforts to curb the 
invasive phenotype of brain tumors have thus far been relatively unsuccessful. Therefore, 
the current study focuses on the invasive aspect of tumor cell biology to better understand 
some of the mechanisms behind their infiltrative nature. 
1.3 Matrix Metalloproteinase Family 
Matrix metalloproteinases (MMPs) are a family of proteins that facilitate 
extracellular matrix remodeling via matrix proteolysis and consequent cell signaling. A 
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family of over 20 proteases, these enzymes can collaboratively degrade every component 
of the extracellular matrix and are involved in biological activities such as wound healing, 
female reproductive tissue regulation, connective tissue development, and inf lamrnat i~n~~~.  
Pathologically, arthritis, cardiovascular disease, emphysema, and cancer are associated 
with ECM destruction, thus MMPs have been shown to play active roles in the matrix 
remodeling occurring in these conditions. 
Matrix metalloproteinases are classified as collagenases, stromelysins, gelatinases, 
or as membrane-type MMPS'. Although each MMP has a slightly different structure and 
substrate specificity, MMPs obtain their proteolytic abilities from a zinc-containing 
catalytic core-domain. A signal peptide, propeptide, and hemopexin domain are also 
conserved components specific to MMPs. Generally secreted in their inactive form, 
removal of the pro domain exposes a zinc binding site within the catalytic domain, 
rendering the enzyme proteolytically active6. Tissue specific inhibitors of matrix- 
metalloproteinases (TIMPs) can inhibit MMP activity by binding to the metal binding site, 
sterically blocking the active site8. However, TIMPs can also activate MMPs. For 
example, although TIMP-2 inhibits MMP-2 activity by binding to the N-terminal catalytic 
domain, TIMP-2 can also assist in the activation of the latent proMMP-2 form to the active 
form when binding to the C-terminal of proMMP-2 '-I2. Different MMPs contain 
additional functional domains to facilitate substrate recognition or aid in transmembrane 
localization and activation. Therefore, MMPs are a somewhat versatile family of 
substrate-specific proteases that are highly regulated and most often expressed during 
periods of matrix remodeling. 
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MMPs are often over-expressed in tumorigenic tissues and elevated MMP levels 
have been shown to correlate with the invasive phenotype of some tumors6. However, in 
the past, the role of matrix metalloproteinases in tumor metastasis may have been 
oversimplified. For years MMPs were only considered proteolytic bulldozers that tore 
through extracellular matrix molecules to clear a path for dividing tumor cells. Because 
cells must bypass the basement membrane in order to reach the bloodstream and 
metastasize in another location, previous theories projected that MMPs aided this process 
solely via matrix proteolysis. However, recent studies suggest that such an assumption 
only acknowledges one mechanism of MMP fi~nctionality. MMPs may play a role in the 
regulation of the availability of bioactive molecules attached to the extracellular matrix; 
proteolysis of ECM components results in the release of these molecules into the 
surroundings to interact with cells7. Other MMP-mediated functions that are associated 
with cancer include suppression of the immune response and the release of angiogenic 
factors to enable tumor cell gro~th38.39. For example, some tumor cells develop escape 
mechanisms that allow them to evade detection by the immune system; MMP-9 can stifle 
T lymphocyte proliferation and MMP- 1 1 can make some tumor cells less sensitive to 
natural killer ~ e l l s ~ ~ - ~ ~ .  MMPs can also induce the production of angiogenic factors such as 
vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and 
transforming growth factor beta to facilitate vascular remodeling and provide a blood 
46-50 supply for growing tumor cells . For example, MMP-9 facilitates the release of 
sequestered VEGF into the surroundings to bind to its receptors and promote 
vasculogenesis. As invasion and metastasis are complex biological processes, MMPs 
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likely promote tumorigenesis through a variety of mechanisms, thus further investigation 
of these proteases, their substrates, and interactions with matrix and non-matrix molecules 
is essential in order to target the specific mechanisms that may facilitate metastasis. 
MMPs bind to both matrix and non-matrix substrates to further tumor progression. 
Although previously viewed solely as matrix obliterators, MMPs have more recently 
become recognized as possible modulators of cell signaling within and beyond the 
extracellular matrix. The extracellular matrix houses many molecules. ECM components 
include proteoglycans, laminin, fibronectin, gelatin, and collagen amongst others and often 
have a strong affinity for non-matrix MMP substrates such as growth factors, integrins, and 
other proteinases. As MMPs chew through the ECM, this destruction results in both 
structural and functional changes to the matrix and the residing molecules. Proteins 
previously bound to matrix components are released into the surroundings as free 
molecules that are now available to bind elsewhere. Further, MMPs have the ability to 
directly cleave certain compounds from their substrates, releasing unbound growth factors 
or other molecules into the surroundings. These bioactive molecules can then bind to a 
receptor to initiate proliferation or apoptotic signaling pathways7. For example, the 
insulin-like growth factor (IGF) system is known to play a role in cell proliferation. The 
cleavage of insulin-like growth factor binding proteins by different MMPs regulates IGF 
bioavailability, perhaps supporting a role for MMPs in tumor cell growth51752. 
Additionally, both pro- and anti-apoptotic pathways are also affected by MMP activity; 
MMP-3 and MMP-7 have been shown to induce apoptosis in epithelial cells whereas 
40-42 MMP- 1 1 can suppress tumor cell apoptosis . 
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MMP expression has been observed in both glioma tissue and glioma cell lines13. 
MMPs-2,7, and 9 have been shown to be over-expressed in gliomas in vitro as well as in 
vivo. Additionally, MMP-1 expression has also been reported to be over-expressed in 
glioblastoma m ~ l t i f o r m e ' ~ - ~ ~ .  Because several of these MMPs are not expressed in normal 
brain, but show elevated expression levels in malignant brain tissues, perhaps MMPs play 
a role in the mechanisms that determine tumor malignancy. 
1.4 Matrix Metalloproteinase-1 
Matrix metalloproteinase- 1, also known as collagenase- 1, fibroblast collagenase, 
and interstitial collagenase, breaks down fibrillar collagens of types I, 11, 111, VII, VIII, and 
X which leads to the consequent degradation of the collagen triple helixg. As a result, 
MMP- 1's proteolytic activity renders the enzyme a powerful matrix obliterator that not 
only destroys matrix components, but binds to a variety of non-matrix substrates as well. 
MMP-1 is similar to many other MMPs in its functional role in matrix remodeling and cell 
signaling. 
Glycosylated MMP- 1 has a molecular weight of roughly 6 1 kDa, but the more 
common unglycosylated form is approximately 57 k ~ a ' ~ .  Similar in structure to many 
other MMPs, collagenase- 1 is composed of a pre-domain, prodomain, zinc-containing 
catalytic region, and a hemopexin domain which aids in substrate specificity 
determination1'. The pre-domain contains a hydrophobic signal sequence to facilitate 
localization to the endoplasmic reticulum and eventual secretion of the enzyme into the 
ECM. The prodomain includes part of what is referred to as the "cysteine switch" which 
regulates the activity or inactivity of the enzyme. Like most MMPs, MMP-1 is secreted as 
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an inactive proenzyme, or zymogen. In its latent form, a cysteine residue binds to a zinc 
ion located in the catalytic domain. Chemical disruption or proteolytic cleavage of the 
cysteine-zinc exposes the catalytic zinc molecule and allows a water molecule to bind, thus 
activating the enzyme3. MMP-1 activity is regulated by different activators and inhibitors, 
including TIMPs and other MMPS". 
Human MMP- 1 expression is usually low in non-pathological circumstances. 
MMP-1 expression increases during periods of wound healing or pathologies that involve 
tissue remodeling such as arthritis, pulmonary emphysema, some fibrotic disorders, and 
cancer18. MMP-1 expression is predominantly regulated at the transcriptional level and is 
controlled by a variety of growth factors, hormones, and cytokines. Different growth 
factors can either increase or decrease MMP- 1 transcription; epidermal growth factor, 
some fibroblast growth factors, hepatocyte growth factor, transforming growth factor 
alpha, and several interleukins have been known to stimulate transcription while 
transforming growth factor beta and some vitamin A derivatives repress protein 
e ~ ~ r e s s i o n ' ~ .  Additionally, MMP-1 promoter sensitivity is highly affected by activator 
protein- 1 (AP- 1) and its various Jun and Fos constituents along with other AP- 1 and E26 
transformation specific(ETS)-related transcription factors8. Cells that generally express 
MMP- 1 include fibroblasts, keratinocytes, chondrocytes, monocytes, and hepatocytes as 
well as many types of tumor cells8 
Matrix nietalloproteinase- 1 has many matrix and non-matrix substrates. In addition 
to its collagenase activity, MMP- 1 can proteolyze other matrix components such as 
aggrecan, versican, perlecan, entactin, gelatin, casein, nidogen, serpins, and tenascin-c". 
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Further, when degradation of these matrix components occurs via MMP- 1 proteolysis, 
other matrix bound molecules are often released into the surroundings. Therefore, MMP-1 
not only degrades ECM elements, but can serve as an indirect force to facilitate the matrix 
release of various growth factors and other matrix bound molecules into the surroundings. 
MMP-I can also cleave non-matrix substrates, characterizing the protease as a 
multifunctional molecule with numerous substrates and downstream consequences; MMP- 
1 has been known to bind to tumor necrosis factor alpha, IL-1 beta, and alphal- 
antichymotrypsin and can also activate proMMP-1 and p r o ~ ~ ~ - 2 7 .  
Absent in normal brain, MMP-1 expression is present in some anaplastic 
astrocytoma and glioblastoma multiforme tumor typesI7. Because the brain contains very 
little collagen, the primary substrate of MMP- 1, few studies involving MMP-1 and its role 
or f~lnction in the brain have been conducted. However, MMP-1 levels have been shown 
to be correlated with the degree of brain tumor malignancy and invasi~eness'~- '~. Recent 
theory projects that MMPs may function as multifunctional molecules; interaction with the 
ECM and its attached proteins may facilitate invasion or proliferation pathways. Further, 
genotyping of the MMP-1 promoter reveals that a single nucleotide polymorphism is 
associated with increased MMP-1 transcription in several cancers. When this 
polymorphism was analyzed in GBM tissue and compared to normal brain, it was shown 
that GBM patients displayed a higher incidence of the allele that facilitates elevated MMP- 
1 e ~ ~ r e s s i o n ' ~ .  Because MMP-1 is only present in the brain under pathological 
circumstances, perhaps MMP- 1 may play a role in the invasive phenotype of human 
gliomas. 
1.5 Experimental design 
The goal of this thesis was to characterize the functional consequences of MMP-1 
over-expression in glioma cell lines. MMP-l 's pathological expression in GBMs suggests 
that MMP-1 is involved in the ability of glioma cells to proliferate and invade surrounding 
tissue. Therefore, the present study aimed to create MMP-1 over-expressing stable glioma 
cell lines which could then be used to analyze invasion and proliferation via collagen 
invasion assays, clonogenic and ATP assays, respectively. MMP- 1 mRNA and protein 
expression were characterized using real-time PCR and Western blot analysis, respectively, 
to determine the relative levels of MMP-1 over-expression in each cell type. Due to the 
novelty of MMP-1 research in brain tumors, the study only attempts to elucidate the 
functional consequences of MMP-1 protein in glioma cell lines and does not probe the 
possible mechanisms of MMP-1 action. We hypothesized that MMP-1 over-expression in 
glioma cells would lead to an increase in invasion and proliferation in vitro. 
CHAPTER 2 Materials and Methods 
2.1 Cell Culture 
The human glioma cell lines T98 and U373 were purchased from American Type 
Culture Collection (ATCC) and maintained in Dulbecco's Modified Eagle's Medium 
(DMEM) with 10% fetal bovine serum (FBS), 1 % L-Glutamine, 1 % nonessential amino 
acids, and 1% penicillin-streptomycin. Cells were maintained at 37OC in an atmosphere of 
5% C02  and 95% humidity. Stably transfected cell lines were maintained with neomycin 
(GIBCO) or puromycin (Sigma-Aldrich) selection media for the T98 and U373 cell lines, 
respectively. The cells were passaged twice a week with Trypsin-EDTA (GIBCOIBRL) 
using sterile tissue culture techniques. Trypan Blue (Sigma) and a hemacytometer were 
used for cell counting. 
In two experiments, LN 1 8, LNZ3 08, U 1 1 8, and U25 1 glioma cells were used. 
LN18, U118, and U25 1 human glioma cells were purchased from the ATCC and LNZ308 
cells were a kind gift from Dr. Erwin VanMeir. These cells were maintained in DMEM 
with FBS, L-Glutamine, nonessential amino acid, and penicillin-streptomycin 
supplementation as noted above. 
2.2 Stable Cell Transfection 
The U373 glioma cell line was transfected with a pIRES-hrGFP- 1 a vector 
(Stratagene) containing MMP- 1 cDNA as well as GFP cDNA (Figure 1). The vector 
utilizes a Cre-mediated site-specific recombination and a Lox P site for insertion of a 
11 
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puromycin resistance gene. Cells were plated in six well plates with DMEM containing 
10% FBS and no antibiotic at a density of 1 x lo6 cells per well. When cells reached 90- 
95% confluency, cells were transfected using Lipofectamine 2000 (Invitrogen) as per the 
manufacturer's protocol. First, 7.5 pL lipofectamine was added to 250 pL serum-free, no 
antibiotic DMEM and incubated at room temperature for five minutes. During this 
incubation period, 4 yg pIRES vector containing MMP-1 cDNA was diluted in 250 pL 
serum-free, no antibiotic DMEM. The diluted lipofectamine and DNA solutions were then 
combined, mixed gently, and incubated at room temperature for 20 minutes. We then 
added 500 pL of the DNAIlipofectamine solution to each well containing cells and 
medium. Cells were incubated at 37OC for approximately 24 hours and then passaged at a 
1 : 10 dilution into 100 mm tissue culture treated plates containing 10% FBS and antibiotics. 
Twenty-four hours later, DMEM containing 10% FBS was removed and a selective 
medium containing 1.5 pg/mL puromycin was added to each plate. The surviving 
puromycin resistant colonies were screened under a fluorescent microscope using a filter 
designed to observe GFP expression (OPELCO Optical). The GFP positive colonies were 
picked using cloning cylinders and subcloned to obtain a more homogeneous cell 
population. For selection maintenance, cells were grown in DMEM containing 1.5 pg/mL 
puromycin. The clone expressing the most GFP when viewed under the fluorescent 
microscope was selected, named (W2A-8), and maintained in puromycin selection media. 
Cells were later subjected to mRNA, protein, invasion, and proliferation analyses. 
A T98 glioma cell line stably transfected with MMP-1 cDNA was also used to 
characterize the effects of MMP-1 over-expression on invasion and cell growth. A vector 
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control (VC2) and three MMP- 1 over-expressing clones (+3, +5, +6) were created in the 
Fillmore laboratory in 2003 by Nermine Abd-Elfattah. Cells were transfected with a p- 
Target vector containing MMP-1 cDNA (ATCC GenBank: X0523 1) with expression 
driven by a CMV promoter (Promega). The vector also contained resistance for G418 
(Invitrogen), a neomycin antibiotic. Lipofectamine 2000 was used to transfect T98 cells 
with 1 pg of the vector DNA and stable clones were selected following treatment with 
G418. For selection maintenance, cells were grown in DMEM containing 330 pg/mL 
G418. These cells were then frozen in DMSO Freezing Medium (BioVeris Corporation) 
and stored at -80°C. In 2006, cells were thawed and passaged several times prior to 
performing the various assays. 
Figure 1. Map of pIRES-hrGFP-la Vector Used in U373 Stable Transfection: U373 
cells were transfected with a pIRES vector containing a dicistronic expression cassette 
which allows MMP-1 and GFP to be expressed on the same transcript. The gene of 
interest was fused to three contiguous copies of the FLAG epitope and a puromycin 
resistance module was inserted into the Lox P site. This figure was obtained from 
Stratagene (La Jolla, California). 
Figure 1. 
The plRES-hrGFP- 1 a Vector 
ampicillin- , 
- - r P  CMV 
LoxF - 
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plRES-hrGFP-1 a Multiple Cloning Site Region 
(sequence shown 65 1-727) 
srf l 
S# I* Sac IIb Na) I* Sma Ifima I BamH I EcoR I 
I I I I I I I 
GA GCT CCA CCG CGG TGG CGG CCG CTC TAG CCC GGG CGG ATC CGA ATT C .. 
w 
I sph ' ? I I 
... GC ATG CGT CGA 
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2.3 RNA Isolation and Real-Time PCR 
RNA was extracted from T98 and U373 cell types using TRIzol Reagent 
(Invitrogen) according to the manufacturer's protocol. Cells were harvested, centrifuged, 
and lysed in 1 mL TRIzol Reagent. Following a five minute incubation period to facilitate 
complete dissociation of nucleoprotein complexes, 200 pL chloroform was added and the 
tubes were vigorously shaken for 15 seconds. Tubes were then incubated at room 
temperature for three minutes and then centrifuged for 15 minutes at 12,000g at 4OC. The 
aqueous phase was transferred to a fresh 1.5 mL eppendorf tube and 0.5 mL isopropyl 
alcohol was added to precipitate the RNA from the aqueous phase. Samples were 
incubated at room temperature for 10 minutes and centrifuged at 1200g for 10 minutes at 
4°C. The RNA pellets were then washed with 1 mL 75% ethanol, vortexed, and 
centrifuged at 7,500g for five minutes at 4OC. Following centrifugation, RNA pellets were 
allowed to air dry and then redissolved in RNase-free water. Spectrophotometry was used 
to quantifL RNA, recording the absorbance at 260 nm. For real-time RT-PCR, RNA 
samples were treated with DNase (Promega) according to the manufacturer's protocol. 
Real-time PCR was performed in the Molecular Core of the VCU Massey Cancer 
Center Nucleic Acids Research Facility using the ABI Prism 7900 Sequence Detection 
System. TaqMan One Step RT-PCR Master Mix Reagents Kit (ABI) was used to prepare 
the samples for RT-PCR and samples were tested in triplicate under four cycling 
conditions: 48°C for 30 minutes, 95°C for 10 minutes, and then 40 cycles at 95OC for 15 
seconds and 60°C for 1 minute. Ribosomal RNA (18s) was used as a control and the 
primers for MMP- 1 were as follows: 
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5'-CAGTGGCAAGTGTTCTTTGG-3' and reverse 5'-CTCCCACCTTTCCCACTGTA-3' 
2.4 Protein Extraction, Conditioned Media Collection, and Quantization 
In order to collect cell lysates and conditioned media for Western blot analysis, 
cells were plated at a density of 2x10~ cells per 100 mm dish in 10% FBS DMEM. Upon 
80% confluency, DMEM containing 10% FBS was removed from cells and replaced with 
4% FBS DMEM. Four hours later, this media was removed, cells were washed with 
phosphate buffered saline (PBS) to remove residual serum, and serum-free DMEM was 
added for 24 hours. Conditioned media was then collected while remaining cells were 
washed with PBS and lysed with 800 pL Radio Immuno Precipitation (RIPA) buffer 
containing protease inhibitors to prevent protein dephosphorylation and denaturation. 
RIPA buffer enables protein solubilization without significant protein degradation and is 
composed of 50 mM Tris-HC1, 150 rnM NaCl, 1% NP-40,0.25% sodium deoxycholate, 
and 0.5% SDS with a final pH of 7.2. Cells were lysed for five minutes on ice with gentle 
agitation, cells were collected using a cell scraper, and cell lysates were centrifuged in a 
4°C cold room at 14,000 rpm for 20 minutes. supernatants were aliquoted and stored at - 
80°C. Conditioned media was concentrated approximately eight-fold using Centricon 
Centrifugal Filter Devices (Amicon Bioseparations) and was stored at -80°C. 
Protein concentrations for cell lysates and conditioned media were determined 
using the Bio-RAD Protein Assay Kit and standards containing 25 pg/mL - 2 mg/rnL 
Bovine Serum Albumin (BSA); BSA was diluted in RIPA or serum free media for lysate 
and media standards, respectively. Lysate and media samples were prepared as per the 
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manufacturer's protocol (Microplate Assay Protocol 5.2) and absorbance was measured at 
670 nm in a FLUOstar (BMG). 
2.5 SDS PAGE Electrophoresis and Western Blot Analysis 
According to the NUPAGE protocol for the NUPAGE Bis-Tris Electrophoresis 
System, cell lysate and media samples were prepared under reducing conditions and heated 
at 85°C for 10 minutes to ensure protein denaturation and complete reduction of disulfide 
bonds. NuPAGE 4-12% Bis-Tris gels were used for sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS PAGE) along with NuPAGE SDS Running 
Buffer (MES) and NuPAGE Antioxidant obtained from Invitrogen. Each well of the gel 
was loaded with 10 pg protein. Following electrophoresis, proteins were transferred to a 
ilitrocellulose membrane (Invitrogen) by using a transfer solution consisting of NuPAGE 
Transfer Buffer, methanol, and antioxidant. Membranes were then incubated at room 
temperature with gentle agitation in 5% non-fat dry milk buffer containing 0.01% SDS for 
one hour to prevent non-specific background binding of the primary or secondary antibody 
to the membrane. In order to detect MMP-1 protein, a mouse monoclonal primary MMP-1 
antibody (R&D Systems, cat# MAB901) was added to the blocking buffer at a dilution of 
1 : 1000. The membranes were then incubated at 4°C overnight with gentle agitation to 
enable adequate homogenous covering of the blot. The following day, the primary 
antibody was removed and the membrane was rigorously washed with a PBS rinse buffer 
containing 1% Tween 20. An anti-mouse monoclonal secondary antibody (Molecular 
Probes Invitrogen; cat# A21036) was then added at a dilution of 1:50,000 in blocking 
buffer for one hour with gentle agitation and protection from light. Following a second 
series of washes with PBS rinse buffer, the membranes were covered in PBS and 
developed using the ODYSSEY Infrared Imaging System (LI-COR Biosciences) located at 
the Hunter Holmes McGuire VA Medical Center. The process was repeated with 
antibodies for MMP-2 (Chemicon; cat# AB808) and cyclophilin detection (Upstate Cell 
Signaling Solutions; cat# 07-3 13); a rabbit MMP-2 primary antibody (diluted 1 : 1000) and 
a rabbit anti-cyclophilin primary antibody (diluted 1:2500) were both used with a 
polyclonal anti-rabbit secondary antibody (Rockland; cat# 6 1 1 - 132- 122) (diluted 1 :50,000 
and 1 :25,000, respectively). 
2.6 Fluorescent Microscopy 
An OPELCO Olympus CK40 fluorescent microscope and a filter designed for GFP 
emission was used to view GFP expression in stably transfected U373 cells. To detect 
GFP microscopically, the microscope contains a Chroma GFP Bypass filter (OPELCO 
Optical) and is connected to a Spot Insight Color camera that utilizes the Spot Advanced 
program to photograph images in phase contrast and fluorescence. 
2.7 In Vitro Collagen I Invasion Assays 
A 96-well Collagen I Cell Invasion Assay kit was obtained from Trevigen in order 
to analyze in vitro invasion of T98 and U373 cells that were stably transfected with MMP- 
1. The assay utilizes a Boyden Chamber which consists of an upper and lower chamber 
separated by an 8.0 pm polyester membrane. The day before plating the cells, the 
membrane was coated with a rat collagen I solution (10 pg/cm2) included in the kit and 
each cell line was gradually reduced from 10% FBS DMEM to serum free DMEM such 
that cells were growing in medium that lacked FBS for 18-24 hours as per the 
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manufacturer's protocol. The appropriate selection media was used for all vector control 
or MMP-1-expressing clones. The cells were harvested and the residual collagen I 
solution was removed from each well in the top chamber. Cells were plated in the top 
chamber at a density of 50,000 or 100,000 cells per well in 50 pL DMEM containing 10% 
FBS and the appropriate selection media. Immediately following cell plating, .the bottom 
chamber was filled with 150 pL DMEM containing 10% FBS and the appropriate selection 
media. Each condition was performed in triplicate and the cells were allowed to invade 
through the collagen membrane for 48 hours at 37°C. Cells were aspirated from the top 
chamber which was then washed with a PBS solution to remove non-invading cells. The 
bottom chamber was aspirated and washed twice with the same PBS solution. Following 
removal of the PBS solution, a calcein AM solution included in the kit was added to each 
well of the bottom chamber. Calcein AM is a hydrophobic compound that permeates the 
cell membrane and, upon hydrolysis, produces calcein, a strongly fluorescent compound. 
After a one hour 37°C incubation period, the top chamber was removed and the bottom 
chamber was read in a fluorescent plate reader at 485 nm excitation and 520 nm emission 
to quantify the fluorescence of invading cells located in the bottom of each well. 
A standard curve was created for each cell line prior to performing the assay such 
to develop a system to correlate the number of invaded cells with fluorescence emission. 
In a 96-well black receiver plate, cells were plated in triplicate at selected concentrations 
ranging from 0 - 100,000 cells per well, treated with calcein AM solution, incubated for 1 
hour at 37OC, and then read on the fluorescent plate reader at 485 nm excitation, 520 nm 
emission. Some experiments utilized the standard curve, using a linear regression equation 
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calculated for each standard to determine the number of cells that invaded through the 
collagen membrane (y = mx+b = avg RFU; x = # of invading cells). In other experiments 
we did not utilize the standard curve, thus in these assays, relative fluorescence units 
(RFU) were used for data analysis. 
One invasion experiment utilized a MMP-1 mouse monoclonal blocking antibody 
(R&D Systems; cat# MAB90 1) and Hepatocyte Growth Factor (HGF)(R&D Systems) 
stimulation to further assess the effects of MMP- 1 on glioma cell invasion in vitro. In this 
experiment, the appropriate antibody dilution (0.1 pg/mL, 1 pg/mL, 10 yg/mL) was added 
to the T98 and U373 cells immediately after cell plating while a separate group of U25 1 
cells underwent HGF stimulation. U25 1 cells were stimulated with a HGF (100 ng/mL) or 
vehicle solution 30 minutes following cell plating, and then incubated for 48 hours prior to 
running the assay. 
2.8 Clonogenic Cell Survival Assay 
Clonogenic assays were used to analyze cell proliferation and the colony-forming 
ability of T98 and U373 parental and stably transfected cell lines. T98 cells were 
harvested and plated in 6-well plates at a density of 600 cells per well whereas U373 cells 
were plated at 1200 cells per well. All cells were plated in a total volume of 3 mL DMEM 
containing 10% FBS. The appropriate selection media was used for each stably transfected 
cell line and the assay was performed in triplicate. The cells were allowed to proliferate 
for nine days in a 37°C incubator. The media was then removed and each well was washed 
with PBS. The cells were fixed with 2 mL 100% methanol per well, incubating at room 
temperature for 30 minutes. After the methanol was removed, cells were stained with 2 
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mL of Giemsa Stain and incubated for 1 hour at room temperature. The Giemsa Stain was 
then removed and each well was washed with nanopure water and allowed to dry. 
Colonies consisting of at least 50 cells were counted under a microscope. 
2.9 ATP Cell Viability Assay 
An ATP assay was used to analyze proliferation from a cell viability standpoint. 
The Promega CellTiter-Glo Luminescent Cell Viability Assay utilizes a thermostable 
luciferase which facilitates the generation of a luminescent signal that is proportional to the 
amount of ATP present, which is in turn proportional to the number of metabolically active 
or viable cells present in culture. The company demonstrates that their product generates a 
linear relationship between relative luminescence units (RLU) and viable cell number. 
Further, the protocol references several studies that support ATP bioluminescence as an 
20-30 accurate technique to measure cell proliferation . 
Cells were plated in opaque 96-well plates at a density of 1500 cells per well in a 
total volume of 100 pL per well. Cells were plated (five replicates) in 10% FBS DMEM 
that contained the appropriate antibiotic selection for stably transfected cells and incubated 
at 37°C. Identical plates were prepared for each day of a time course spanning Days 1,3, 
5, and 7; Day 1 luminescence was recorded 24 hours after plating and so forth for the other 
three time points. For each time point, the assay was performed according to the 
manufacturer's protocol; the 96-well plate and its contents was equilibrated to room 
temperature for 30 minutes as were the CellTiter-Glo Buffer and CellTiter-Glo Substrate 
included in the kit. The CellTiter-Glo Buffer was then transferred into the bottle 
containing CellTiter-Glo Substrate to reconstitute the lyophilized enzymelsubstrate 
mixture. This CellTiter-Glo Reagent was then added to each well of the 96-well plate for 
the appropriate time point at a volume of 100 pL per well. Each plate was mixed on an 
orbital shaker for 2 minutes to induce cell lysis and then incubated at room temperature to 
allow the luminescence signal to stabilize. Ten minutes later, luminescence was recorded 
on a Packard Top Count NXT Microplate Scintillation and Luminescence Counter located 
at the Hunter Holmes McGuire VA Medical Center. 
2.10 Statistical Analysis 
For T98 cells, an Analysis of Variance (ANOVA) followed by Dunnett's Post Hoc 
test was used to determine differences between MMP-1 over-expressing clones (+3, +5, 
and +6) and the T98 vector control. For experiments requiring the comparison of more 
than two groups without a defined control, an ANOVA followed by Tukey's HSD Post 
Hoc test was performed. For analysis of data comparing only two groups, such as 
experiments involving the MMP-1 over-expressing clone W2A-8 and the U373 parental, a 
Student's t-Test was utilized. All p values <0.05 by Student's t-Test and Tukey and 
Dunnett's Post Hoc tests were considered significant. 
CHAPTER 3 Results 
3.1 Confirmation of Transfection Efficiency 
In order to confirm that T98 and U373 cells were successfully transfected with 
MMP- 1 cDNA, real-time RT PCR, Western blot analysis, and fluorescent microscopy 
were utilized to characterize mRNA and protein expression. MMP-1 mRNA levels were 
detectable in T98 cells that were stably transfected with MMP-1 cDNA (Figure 2). Cells 
from the +3 clone display significantly higher MMP-1 mRNA levels relative to the VC2 
vector control (p<0.05), but no statistical difference is observed when comparing +3 
mRNA levels to the T98 parental control (Figure 2). In addition, MMP-1 mRNA levels in 
+3 cells are significantly higher than mRNA levels in the +6 clone (p<0.05). These results 
are mirrored in Western blot analysis. Figure 3 illustrates protein expression in stably 
transfected T98 cells. Recombinant MMP-1 protein (R&D Systems; cat# WBC024) 
served as a positive control for Western blot analysis and is identified at molecular weights 
of 55 kDa and 53 kDa. Concentrated conditioned media (8-fold) from the MMP-1 stably 
transfected T98 clones, +3 and +5, contained elevated levels of MMP-1 protein when 
compared to the vector and parental controls (Figure 3a). However, MMP-1 protein is also 
present in conditioned media from T98 parental and vector control cells, confirming that 
T98 cells produce basal MMP- 1 protein. The MMP-1 stably transfected +6 clone 
expresses low levels of MMP-1 protein (Figure 3a). 
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Analysis of conditioned media that was not concentrated illustrates that the +3 and 
+5 clones demonstrate heightened MMP-1 expression when compared to the two controls, 
but this increase is less pronounced (Figure 3b). Again, the +6 clone appears to be 
expressing only low levels of MMP-1, in accordance with the mRNA data. Because 
MMP- 1 is a secreted protein, cell lysates contain very little MMP- 1 protein and only faint 
expression can be observed via Western blot (Figure 3b). 
U373 glioma cells were transfected with a pIRES expression vector construct 
containing cDNA for both MMP-1 and GFP. In the U373 parental cell line, there is no 
MMP-1 rnRNA detectable using real-time RT PCR (Figure 4). However, in the stably 
transfected clone (W2A-8), high levels of MMP- 1 mRNA were observed, a difference that 
was clearly significant (p<0.05) (Figure 4). Western blot analysis reveals similar results; 
MMP- 1 protein is absent in the U373 parental cells and over-expressed in W2A-8 cells 
(Figure 5). Additionally, fluorescent microscopy was utilized to observe GFP expression 
in transfected U373 cells. The majority of the W2A-8 cells are GFP positive when viewed 
under a fluorescent microscope whereas parental cells do not display any green 
fluorescence (Figure 6a). In addition to the mRNA and protein assays examining MMP-1 
expression, this illustrates that GFP expression is correlated with MMP- 1 expression in the 
W2A-8 clone. 
Figure 2. MMP-1 mRNA Levels in Stably Transfected T98 Cells: RNA was extracted 
from T98 parental and transfected cells and subjected to real-time RT-PCR for MMP-1 
mRNA quantification (N=l). MMP- 1 mRNA levels were normalized to the 18s rRNA 
and the averages of the triplicate values are plotted; error bars represent standard 
deviations. Asterisks * denote statistical differences as determined by Tukey's HSD Post 
Hoc test (p<0.05). 
Figure 2. 
T98 Cells - MMP-1 mRNA Levels 
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Figure 3. MMP-1 Protein Expression in Stably Transfected T98 Cells: Conditioned 
media (CM) and cell lysates were collected from each cell type and proteins were 
separated on a 4-12% polyacrylamide gel (N=4). Recombinant MMP-1 protein was loaded 
as a positive control. Following electrophoresis, proteins were transferred to a 
nitrocellulose membrane and probed for MMP-1 using a mouse monoclonal antibody 
diluted 1 : 1000. An antibody against cyclophilin A (CypA) was used to control for lysate 
protein loading. Figures 3a and 3b illustrate two separate Western blots with concentrated 
(8-fold) media and 3b includes conditioned media that was not concentrated. 
53 kD - Cell lysate - MMP-1 
18 kD- 
, . . Cell lysate - CypA 
53 kD - CM (not concentrated) 
- MMP-1 
I 
53 kD - Cell lysate - MMP-1 
Cell lysate - CypA 
Figure 4. MMP-1 mRNA Levels in Stably Transfected U373 Cells: RNA was extracted 
from U373 parental and MMP-1 transfected cells and subjected to real-time PCR for 
MMP-1 mRNA quantification (N=l). MMP-1 mRNA levels were normalized to the 18s 
rRNA and the averages of the triplicate values are plotted; error bars represent standard 
deviations. The asterisk * represents a statistical difference between W2A-8 and parental 
cells as determined by a Student's t-Test (p<0.05). 
Figure 4. 
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Figure 5. MMP-1 Protein Expression in Stably Transfected U373 Cells: Conditioned 
media and cell lysates were collected from U373 parental and W2A-8 cells (N=2). 
Recombinant MMP-1 protein was loaded as a positive control. Proteins from concentrated 
conditioned media and cell lysates were separated on a 4-12% polyacrylamide gel, 
transferred to a nitrocellulose membrane, and probed for MMP- 1 using a mouse 
nlonoclonal antibody diluted 1 : 1000. An antibody against cyclophilin A was used to 
control for lysate protein loading. 
Figure 5. 
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Figure 6. GFP Expression in U373 Cells Stably Transfected with MMP-1IGFP cDNA: 
GFP expression was visualized in transfected U373 cells (W2A-8) using a fluorescent 
microscope, illustrating cells were successfully transfected with the pIRES-hrGFP-1 a 
vector. Cells were photographed (20x magnification). In the left photographs, cells are 
viewed in phase contrast (PC) and the right photographs show cells viewed using a GFP 
fluorescent filter in the same field of view. 
6a. U373 Cells 
PC - 20X objective orescence - 20X objective 
6b. W2A-8 Cells 
PC - 20X objective Fluorescence - 20X objective 
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3.2 Cell Invasion 
To analyze the effect of MMP-1 over-expression on the invasive phenotype of 
glioma cells, we performed collagen type-I cell invasion assays. These assays allowed us 
to compare the invasive capacity of MMP-1 over-expressing cells to parental or vector 
control cells by using collagen type-I coated membranes through which invasive cells 
could migrate. Fluorescence values or invasion percentages (derived from a standard 
curve) were calculated and normalized, comparing each MMP-1 transfected cell line to the 
parental or vector controls. The fold increase in invasiveness was calculated for MMP-1 
over-expressing T98 clones by dividing RFU or percent invasion values by the 
corresponding average vector control value for each experiment. Combined data reveals 
that the MMP- 1 over-expressing +3 clone is significantly more invasive than the vector 
control (p<0.05) (Figure 7). Although the +5 and +6 clones had a tendency to display 
higher RFU or percent invasion values relative to the vector control, no significant 
difference was observed (Figure 7). 
MMP-1 over-expression in U373 cells revealed invasion results similar to those 
observed in the +3 T98 clone; MMP-1 over-expressing U373 cells (W2A-8) were more 
invasive than parental control cells (Figure 8). For each experiment, the W2A-8 fold 
increase in invasiveness was calculated by dividing W2A-8 RFU values by the RFU 
average in U373 control cells. Combined data from three experiments reveals that MMP-1 
over-expressing W2A-8 cells are significantly more invasive than the U373 parental cells 
(p<0.05). 
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After characterizing the invasive phenotype of T98 and U373 cells that were stably 
transfected with MMP-1 cDNA, these clones were compared to several other glioma cell 
lines to further analyze invasion. In a single experiment, the LN18, LNZ308, U118, and 
U25 1 cell lines were assayed for invasion and compared to both the transfected and 
parental U373 and T98 cell lines. Comparing the average RFU values from the various 
cell lines illustrates that U373 and T98 parental cells are less invasive than the other four 
glioma cell lines (Figure 9a). However, several of the U373 and T98 transfected clones 
were more invasive than the LN18, LNZ308, U118, and U25 1 cell lines assayed in this 
experiment. The +3 clone was shown to be significantly more invasive than all six 
parental cell lines, while the W2A-8 clone demonstrates a significant increase in 
invasiveness when compared to the LN18, U373, and T98 parental cells (p<0.05) (Figure 
9b, Table 1). For clarity, Table 1 illustrates the transfected cell lines displaying statistical 
differences in invasion when compared to the non-transfected glioma cell lines from Figure 
9b. 
Because two MMP-1 over-expressing clones displayed a significant increase in 
invasion when compared to the corresponding T98 and U373 controls, we performed an 
invasion assay utilizing a MMP- 1 blocking antibody to further assess the effect of MMP- I 
protein on invasion in vitro. Three dilutions (0.1 - 10 pg/mL) of the neutralizing MMP-1 
mouse monoclonal antibody were applied to the parental and transfected cells assayed in 
the experiment. RFU values were averaged and compared to control cells, which did not 
receive MMP- 1 blocking antibody. Figure 10 illustrates the MMP- 1 neutralizing effect on 
T98 parental, vector control, and MMP- 1 transfected cells from a single experiment. There 
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was no significant difference within the separate cell lines when comparing the three 
antibody dilutions, indicating that the MMP-1 blocking antibody did not significantly 
affect the invasive phenotypes of these glioma cells. A similar response in U373 cells was 
observed; addition of the neutralizing antibody did not significantly affect the invasiveness 
of U373 or W2A-8 cells (Figure 11). 
In addition to analyzing the effect of MMP- 1 neutralization on invasion in vitro, 
MMP- 1 stimulation with HGF was also performed to further assess the invasive phenotype 
of gliomas. HGF stimulation has been shown to induce MMP- 1 expression in the U25 1 
glioma cell line (data not shown). Therefore, an invasion assay was performed on U25 1 
cells that were stimulated with 100 ng HGF per mL of solution. There was a significant 
increase in the average RFU of cells stimulated with HGF when compared to cells that 
received a vehicle solution (p<0.05) (Figure 12). However, when compared to control 
cells that did not receive a vehicle solution, no difference in invasiveness was observed 
(Figure 12). 
Figures 7. Invasiveness of T98 Cells Stably Transfected with MMP-1 cDNA: Cell 
lines were assayed for invasion through collagen type-I coated membranes and 
luminescence or percent invasion based on luminescence values were averaged for each 
experiment (N=4). Invasion of MMP- 1 over-expressing clones is expressed relative to the 
vector control as a fold increase in invasiveness. The graph represents the combination of 
four separate experiments and each experiment was performed in either triplicate or eight 
replicates. Error bars represent standard error. Asterisks * indicate a significant increase 
in invasiveness when compared to the vector control, reflecting a p value < 0.05 by 
Dunnett's Post Hoc test. 
Figure 7. 
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Figure 8. Invasiveness of U373 Cells Stably Transfected with MMP-1 cDNA: Cell 
lines were assayed for invasion through collagen type-I coated membranes and 
luminescence values were averaged for each experiment (N=3). Invasion of the MMP-1 
over-expressing W2A-8 clone is expressed relative to the U373 parental cell line as a fold 
increase in invasiveness. The graph represents the combination of three separate 
experiments and each experiment was performed in either triplicate or eight replicates. 
Error bars represent standard error. Asterisks * indicate a significant increase in 
invasiveness when compared to the parental control, reflecting a p value < 0.05 by 
Student's t-Test. 
Figure 8. 
--- 
U373 Cells - Cell lnvasiveness 
Figure 9. Relative Cell Invasiveness of Glioma Cell Lines Compared to Cells 
Transfected With MMP-1 cDNA: Six glioma cell lines and all stably transfected cells 
were assayed for invasion and luminescence values were recorded (N=l). The average 
RFU is plotted as the average of eight replicates from a single experiment. Error bars 
represent standard deviations. Both figures represent identical data from the same 
experiment and were divided for clarity. Asterisks * display an increase in invasiveness 
relative to both the U373 and T98 parental cell lines by Tukey's HSD Post Hoc test (all p 
values < 0.05). Statistical differences between cells transfected with MMP-1 and other 
glioma cell lines are represented in Table 1. 
Glioma Cell lnvasiveness 
Glioma Cell Invasiveness 
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Table 1. Statistical Comparison of Invasiveness of MMP-1 Transfected Cells Relative 
to Glioma Cell Lines: This table displays the statistical data from cells represented in 
Figure 9b, illustrating the differences in invasiveness between cells that were stably 
transfected with MMP- 1 and non-transfected glioma cell lines assayed in this experiment. 
All boxes labeled with an asterisk * indicate a statistical difference between the 
corresponding cell types as determined by Tukey's HSD Post Hoc test (all p values < 
0.05). 
Table 1. 
Non-Transfected Glioma Cell Lines 
Figure 10. Invasiveness of T98 Cells with MMP-1 Neutralization: T98 parental, vector 
control, and MMP-1 transfected cells were assayed for invasion after the addition of a 
MMP-1 blocking antibody. The data is representative of a single experiment (N=l) that 
was performed in triplicate and average W U  is plotted as the mean fluorescence from each 
cell type within the specified antibody dilution. Error bars represent standard deviation. 
An ANOVA analysis revealed that there were no significant differences in invasiveness 
within the cell types upon the addition of antibody. 
Figure 10. 
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Figure 11. Invasiveness of U373 Cells with MMP-1 Neutralization: U373 and MMP-1 
transfected cells from the W2A-8 clone were assayed for invasion after the addition of a 
MMP-1 blocking antibody. The data is representative of a single experiment (N=l) that 
was performed in triplicate and average RFU is plotted as the mean fluorescence from each 
cell type within the specified antibody dilution. Error bars represent standard deviation. 
An ANOVA analysis revealed that there were no significance differences in invasiveness 
within U373 or W2A-8 cells upon the addition of antibody. 
Figure 11. 
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Figure 12. Invasiveness of U251 Cells Stimulated with HGF: Following stimulation 
with HGF or a vehicle solution, cells were assayed for invasion through collagen type-I 
coated membranes and RFU values were averaged for each group. The data is 
representative of a single experiment (N=l) that was performed in triplicate. Error bars 
represent standard deviations. The asterisk * indicates a statistical difference between the 
U25 l+HGF and U25 l+Vehicle cells as determined from a Student's t-Test (p<0.05). 
Figure 12. 
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3.3 Cell Viability and Proliferation 
Clonogenic and ATP viability assays were used to characterize the effects of 
MMP- 1 over-expression in glioma cells on cell proliferation. Clonogenic assays measure 
proliferation by analyzing the colony-forming abilities of cell lines whereas the ATP assay 
quantitates the number of metabolically active, or viable cells. Figure 13 depicts the 
number of colonies formed when T98 parental, vector control, and MMP-1 over- 
expressing cells were plated at a cell density of 600 cells per well and analyzed for 
clonogenic survival. The +3 and +5 MMP- 1 transfected clones displayed a significant 
increase in colony formation when compared to the vector control (p<0.05). However, 
statistical significance was not obtained when the +3 and +5 clones were compared to the 
T98 parental cell line. Although there was a trend in each separate experiment for the +6 
clone to display a higher level of clonogenicity over the parental and vector controls, 
statistical significance was not achieved. Although the W2A-8 clone had a tendency to 
form more colonies than the U373 parental when plated at a density of 1200 cells per well, 
statistical significance was not observed (Figure 14). 
ATP content of glioma cells was measured on Days 1,3, 5, and 7 following cell 
plating using the CellTiter-Glo Luminescent Cell Viability Assay. T98 parental and 
transfected cells were analyzed for statistical differences in cell viability within each day 
(Figure 15). The statistical analysis from Day 7 was excluded due to the drastic decrease 
in cell number, most likely a result of cell over-growth. Although Figure 15 illustrates that 
there were some statistical differences in cell viability throughout Days 1-5 (all p values < 
0.05), a clear growth pattern between the different cell types was not observed. Figure 16 
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illustrates cell viability in U373 parental and W2A-8 cells. On Day 7, the MMP-1 
transfected cells displayed a significant decrease in RLU relative to the parental cell line 
(p<0.05). 
Figure 13. Clonogenic Cell Survival of T98 Cells Over-Expressing MMP-1: 
T98 parental, vector control, and MMP- 1 transfected cells were plated at 600 cells per well 
and analyzed for clonogenic survival nine days later. The number of colonies is presented 
as the average number of colonies formed per well when performed in triplicate and 
combines data obtained from three separate experiments (N=3). Error bars represent 
standard error. Asterisks * denote statistical differences relative to the vector control and 
display p values < 0.05 by Dunnett's Post Hoc test. 
Figure 13. 
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Figure 14. Clonogenic Cell Survival of U373 Cells Over-Expressing MMP-1: 
U373 parental and MMP-1 transfected cells from the W2A-8 clone were plated at 1200 
cells per well and analyzed for clonogenic survival nine days later. The number of 
colonies is presented as the average number of colonies formed per well when performed 
in triplicate and combines the data from three separate experiments (N=3). Error bars 
represent standard error. No statistical difference in clonogenicity was observed using a 
Student's t-Test. 
Figure 14. 
U373 Cells - Clonogenic Cell Survival 
Figure 15. Cell Viability and Growth of T98 Cells Over-Expressing MMP-1: T98 
parental and transfected cells were subjected to the ATP luminescent cell viability assay on 
selected days. The average of five replicates is plotted as the average RLU and is a 
representative of two experiments (N=2). Error bars represent standard deviations. 
Asterisks * indicate a significant difference in cell viability when compared to the vector 
control for each corresponding day as determined by Tukey's HSD Post Hoc test. All p 
values < 0.05 were considered significant. Other comparisons were statistically significant 
but are not shown for purposes of clarity. 
Figure 15. 
T98 Cells - Cell Viability by ATP Assay 
Figure 16. Cell Viability and Growth of U373 Cells Over-Expressing MMP-1: 
U373 and W2A-8 cells were subjected to the ATP luminescent cell viability assay on 
selected days. The average of five replicates is plotted as the average RLU and combines 
data from three separate experiments (N=3). Error bars represent standard error. The 
asterisk * between U373 and W2A-8 cells on Day 7 indicates a significant difference in 
cell viability as determined by a Student's t-Test (p<0.05). 
Figure 16. 
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3.4 MMP-2 Expression in Cells Over-Expressing MMP-1: 
Because MMP-1 is a known activator of MMP-2 protein, we analyzed MMP-2 
protein levels in cells that were transfected with MMP- 1; perhaps MMP- 1 over-expression 
facilitates an increase in MMP-2 activation. MMP-2 protein is secreted into the media in 
very high amounts, even in the parental cell lines and T98 vector control (Figure 17). The 
Western blot reveals three forms of MMP-2 expression: pro-MMP-2 located at 72 kDa, an 
intermediate form located at 64 kDa, and active MMP-2 protein located at 62 kDa. 
Because T98 and U373 cells secrete large quantities of basal MMP-2 into the surrounding 
media, it is difficult to determine if the MMP-1 over-expressing cell lines are expressing 
elevated levels of active MMP-2. A Western blot illustrating MMP-1 protein over- 
expression in the +3, +5, and W2A-8 clones is included to compare MMP-1 over- 
expression with MMP-2 protein levels from the same conditioned media. Subjectively, the 
MMP-1 over-expressing clone +3 shows a slight increase in the active 62 kDa form of 
MMP-2, while the W2A-8 clone shows no apparent difference in enzyme activity when 
compared to the U373 control. However, the lack of a proper loading control inherent in 
examination of conditioned media makes these observations inconclusive. 
Figure 17. MMP-2 Expression in T98 and U373 Cells Stably Transfected with MMP- 
1: Conditioned media (CM) and cell lysates were collected fi-om T98 and U373 parental 
and transfected cells. Protein from concentrated conditioned media and cell lysates was 
separated, transferred to a nitrocellulose membrane, and probed for MMP-2 using a rabbit 
MMP-2 antibody diluted 1 : 1000. An antibody against cyclophilin A (CypA) was used to 
control for lysate protein loading. A Western blot illustrating MMP- 1 expression is also 
shown to compare MMP-1 and MMP-2 protein levels in the corresponding cell types. 
Figure 17. 
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CHAPTER 4 Discussion 
Although studies have reported that glioblastomas and some anaplastic 
astrocytomas contain elevated MMP- 1 protein levels, few studies involving MMP- 1 and its 
potential role in brain tumor biology have been conductedI7. MMP-1 is not expressed in 
normal brain, thus its pathological presence in these brain tumor types warrants further 
investigation of MMP- 1 function in brain tumor growth and metastasis. Characterization 
of the effects of MMP-1 over-expression in two glioma cell lines has resulted in data 
which suggest that MMP-1 may play a role in tumor cell invasion and clonogenic survival. 
The results of the invasion and proliferation assays that were performed in this 
study appear to be dependent upon the MMP-1 over-expressing cell lines created in the 
Fillmore laboratory. In the T98 glioma cell line, MMP-1 over-expression is observed in 
the +3 clone. Real-time RT-PCR showed that the +3 clone displayed an increase in MMP- 
1 mRNA relative to the vector control. Western blot analysis mirrored these results by 
indicating elevated protein levels in the +3 clone when compared to the parental and vector 
controls. Although Western blot analysis also revealed an increase in MMP- 1 protein 
expression in cells from the +5 clone, mRNA levels were no different from the controls. 
As noted above, T98 cells produce MMP-1 protein under basal conditions. Further, MMP- 
1 production is often heightened during periods of stress. For this reason, Western blot 
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analyses may be less definitive, as we observed some variability when comparing blots 
from different conditioned media collections. Therefore, perhaps the overall health of the 
cells affects the amount of MMP-1 mRNA and protein expression observed in T98 
parental and transfected cells. We will focus on the results of the +3 clone in order to 
analyze the functional consequences of MMP-1 over-expression. In addition, the +5 clone 
will also be analyzed as it expressed elevated protein levels, despite no difference in 
mRNA expression when compared to the parental or vector controls. 
For the U373 cells, real-time RT-PCR and Western blot analyses indicate that the 
W2A-8 clone over-expresses MMP-1 mRNA and protein, respectively. Because U373 
glioma cells do not produce MMP- 1 under basal conditions, the differences in MMP- 1 
expression between the U373 parental and W2A-8 clone are well delineated. Further, 
fluorescent microscopy reveals that the majority of the W2A-8 cells are GFP positive. 
Therefore, W2A-8 cells appear to be over-expressing MMP-1 and can be used to study the 
effects of MMP- 1 over-expression on invasion and proliferation. 
The data presented suggests that MMP- 1 over-expression may play a role in the 
invasive phenotype of human gliomas. In T98 cells, the MMP- 1 over-expressing +3 clone 
was shown to be more invasive than the vector control. This effect was mirrored in the 
U373 cell line; the MMP-1 over-expressing W2A-8 clone was more invasive than the 
parental control. T98 and U373 transfected cells were compared to four additional glioma 
cell lines to analyze the relative invasiveness of MMP-1 over-expressing cells. When 
comparing LN18, LNZ308, U118, U251, U373, and T98 glioma cell lines to each other, 
U373 and T98s are the two least invasive cell types. However, when T98 cells were 
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transfected with MMP- 1, the MMP- 1 over-expressing +3 clone was more invasive than all 
six human glioma cell lines assayed, including the most invasive U25 1 cell line. A similar 
effect was observed in U373 cells, although the increase is less pronounced; MMP-1 over- 
expressing W2A-8 cells were more invasive than LN18, T98, and U373 parental cell lines. 
Therefore, MMP-1 over-expression results in a functionally significant increase in cell 
invasion; cells that are normally less invasive become transformed to a more highly 
invasive phenotype. These results support a role for MMP- 1 in glioma invasion. 
In order to analyze the effects of MMP-1 over-expression on cell growth, we 
assessed the colony-forming abilities of the different cell types along with the viability of 
these cells via ATP content quantification. In T98 cells, the +3 and +5 clones were both 
more clonogenic than the vector control. However, when compared to T98 parental cells, 
no statistical difference in clonogenicity was observed. In U373 cells, there was no 
difference in clonogenic survival when comparing the MMP-1 over-expressing W2A-8 
clone to the parental control. In summary, MMP- 1 over-expression resulted in an increase 
in clonogenic survival in T98 cells but not in the U373 cell line. 
In a cell proliferation assay as measured by the CellTiter-Glo Luminescent Cell 
Viability kit, the T98 control and transfected cells appear to be proliferating on Days 1,3, 
and 5, representing the growth phase of the time course. On Day 7, a dramatic decrease in 
cell number was observed in three of the cell types, indicating that these cells likely 
became over-grown. Therefore, Day 7 results were excluded from the statistical analysis. 
On Day 3, MMP-1 over-expressing +3 cells were more viable than the vector control, but 
this observation was an isolated event and was not consistent throughout the time course. 
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Overall, no overwhelming difference in growth pattern was observed. However, because 
this experiment was performed only twice, it may be beneficial to reanalyze cell viability 
by repeating the experiment. Plating cells at a lower density may help prevent over- 
growth, extending the growth phase so that viability can be assessed throughout the entire 
time course. 
Results from the ATP assay on U373 cells showed that MMP- 1 over-expressing 
cells fkom the W2A-8 clone were less proliferative on Day 7 than U373 parental cells. In 
contrast to the T98 cells, the U373 parental and transfected cells displayed a steady 
increase in cell growth throughout the entire time course and a clearer pattern of cell 
growth was observed. 
When analyzing the data from the current study, we must acknowledge certain 
factors that affected the results from invasion and proliferation assays. The overall health 
of each cell type may have played a role in the invasive and proliferative characteristics 
observed in this study. As noted earlier, T98 cells produce basal MMP-1 protein. 
Consequently, both the parental and vector controls produce some MMP-1. Stressful 
conditions, such as when cells become overgrown or nutrient-deprived, can lead to 
increases in MMP-1 production in T98 cells. The invasion assays required that cells 
undergo serum starvation for 24 hours prior to performing the assay. Although care was 
taken to ensure that only healthy cells were used in the various assays, some cells may 
have been experiencing more stress than others before and during experimentation. If T98 
or vector control cells were experiencing stressful conditions, an increase in MMP-1 
production could cause the controls to mirror the possible invasive phenotype of MMP- 1 
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over-expressing cells. Therefore, cell health may have played a crucial role in the results 
of the various invasion and proliferation assays as T98 cells can produce varying levels of 
MMP- 1 depending on their surro~~nding conditions. 
The goal of the present study is to analyze the functional consequences of MMP-1 
over-expression in human glioma cells. After determining that the +3 and W2A-8 MMP-1 
over-expressing clones were more invasive than the vector and parental controls, 
respectively, the next step was to determine if MMP-1 over-expression is a potential cause 
of the invasive phenotype. To do this, we assayed cell invasion when in the presence of an 
MMP- 1 blocking antibody. Although MMP- 1 neutralization did not affect invasion in T98 
or U373 cells, the experiment was performed only once and the antibody dilutions had not 
been tested to see which concentrations could sufficiently block MMP-1 protein activity. 
Further, the methodology may need adjusting; we had not performed collagen invasion 
assays using blocking antibodies in the past, thus there are many optimization steps that 
should be completed before repeating the experiment. 
In addition to analyzing the effect of MMP-1 neutralization on cell invasion, we 
also evaluated cell invasion following MMP-1 induction; U25 1 cells were stimulated with 
HGF to induce MMP-1 protein expression. Cells that were stimulated with HGF were 
more invasive than cells that received a vehicle solution. However, no difference in 
invasiveness was observed when comparing HGF-stimulated cells to U25 1 cells that 
received neither HGF nor vehicle. This observation supports our hypothesis that an 
increase in MMP-1 expression may facilitate an increase in invasion. However, these 
results were taken from one experiment and need to be repeated. 
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Because MMP-1 is a known activator of proMMP-2, we analyzed MMP-2 protein 
expression in MMP- 1 over-expressing cells. MMP- 1 and MMP-2 are both secreted 
proteins. Therefore, following translation, these proteins are directed toward the cell 
surface and secreted outside of the cell membrane. Once both peptidases are secreted into 
the extracellular matrix, MMP- 1 can activate proMMP-2. Western blot analysis of T98 
and U373 cells reveals that both parental cell lines produce high levels of MMP-2 protein 
consistent with published reports of MMP-2 expression in glioma cell lines. In 
conditioned media, a slight increase in pro and active MMP-2 is observed in the MMP- 1 
over-expressing +3 clone. This observation corresponds to the Western blots probing for 
MMP- 1 ; the +3 clone shows heightened MMP- 1 protein expression in conditioned media. 
However, the absence of a loading control (such as cyclophilin A or beta actin for cell 
lysates) for both Western blots makes the relationship between MMP-1 and MMP-2 
protein expression difficult to assess because human glioma cell lines will have high levels 
of MMP-2 secreted proteins. When cell lines already secrete pro and active MMP-2, the 
likelihood of detecting small but significant differences may be difficult. There is no 
visible difference in active MMP-2 expression in U373 cells when compared to MMP- 1 
over-expressing cells. Due to the significant MMP-1 protein elevation observed in W2A-8 
cells, this observation countered our expectations; we hypothesized that W2A-8 cells 
would show an increase in MMP-2 activity. Again, the lack of a loading control makes 
these comparisons difficult. Future studies could use a gelatin substrate gel to better 
determine MMP-2 activity in MMP-1 over-expressing cells when compared to parental or 
vector controls. 
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When interpreting the overall results of this study, we observed a relationship 
between MMP-1 over-expression and the invasive and proliferative phenotypes of these 
cells. When the MMP-1 over-expressing +3 clone is compared to the vector control, +3 
cells demonstrate an increase in MMP-1 mRNA, cell invasiveness through a collagen 
membrane, and clonogenicity. However, when +3 cells are compared to the T98 parental 
control, no differences in mRNA quantity, cell invasiveness, or clonogenic survival are 
observed. 
Although the differences between the two controls raises some questions as to why 
this may be occurring, the relationship between MMP-1 over-expression, invasion, and 
clonogenicity is consistent, regardless of which control is used. This relationship supports 
our hypothesis that MMP-1 over-expression may play a role in invasion and proliferation 
pathways. Due to the differences observed in the T98 parental and vector controls, the 
establishment of a vector control for the U373 cell line will be an important next step in 
continuing the analysis of the functional consequences of MMP- 1 over-expression in 
glioma cell lines. 
Overall, our findings that MMP- 1 over-expression may facilitate an increase in cell 
invasion and proliferation are not surprising. MMPs have been implicated as possible 
mediators of cell growth and proliferation in both normal and malignant cells. MMP- 1 
expression has also been linked to invasion in several different types of cancers. It has 
been reported that MMP-1 is involved in esophageal carcinoma invasion, invasion of 
squamous cell carcinoma of the head and neck, and that MMP- 1 suppression in malignant 
melanoma cells decreases in~asion~'. '~. Further, a recent study showed that MMP- 1 
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inhibition facilitates a decrease in human chondrosarcoma invasion34. One of the critical 
components of tumor cell invasion is penetration through the basement membrane. As a 
collagenase, MMP-1 has the ability to destroy collagen components within the basement 
membrane5. In human glioma cell lines, it has been reported that the rate of glioma cell 
collagen type-I invasion increases with increasing MMP-I, MMP-2, and MMP-9 
expression35. However, MMP- 1 characterization in the brain remains ambiguous; a 
defined role for MMP- 1 in invasion and the mechanisms of MMP- 1 action in brain tumor 
biology have yet to be reported. 
Future Directions: One of the goals of this project was to create a stable cell line 
that over-expresses MMP-1 protein. The W2A-8 clone has been shown to over-express 
MMP-1 and a next step will be to create an appropriate vector control. We have tried to 
transfect U373 cells with a control vector on several occasions, but thus far have been 
unsuccessful. Perhaps increasing the vector DNA concentration or transfecting with a 
different control vector construct will improve the outcome. The creation of an additional 
cell line with multiple clones that over-express MMP-1 protein would be beneficial in 
future studies. Further, MMP- 1 blocking experiments could also be performed to more 
clearly define MMP-1 function in glioma cells. Does blocking MMP-1 expression 
facilitate a decrease in invasiveness or clonogenicity? It may also be of interest for future 
studies to analyze the effects of MMP- 1 over-expression in vivo. MMP- 1 over-expressing 
cells could be injected into nude mice to observe the invasive and proliferative capabilities 
of these cells. 
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To better understand the function of MMP- 1 in human glioblastoma, future studies 
should explore the possible mechanisms of MMP-1 action. MMP-1 may play a role in the 
IGF-1 signaling pathway, a system that is known to affect the growth of both normal and 
cancer cells36. There are reports of MMP-1 cleaving IGFBP-3 from IGF-1, thereby 
releasing IGF- 1 into the surroundings to potentially affect cell proliferation7. Further, 
IGFBP-3 may function to induce apoptosis37. Future studies may want to examine the 
relationship between MMP-1 and the IGF-1 system to explore possible IGF-11IGFBP-3 
cleavage by MMP- 1 and the downstream effects on cell proliferation and apoptotic 
pathways. 
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